Octreotide

【Product name】Sandostatin, ANDOSTATIN

[English common name]Octreotide

[Chinese common name]Octreotide

[English name]CCRIS 8708, L-Cysteinamide, UNII-75R0U2568I, SMS 201-995, L-Cysteinamide, 

[Chinese other name]

[indications]
Octreotide acetate:
1. Emergency treatment of esophageal-gastric varices bleeding caused by cirrhosis, combined with special treatment (such as endoscopic sclerotherapy).
2. Alleviate the symptoms and signs associated with gastrointestinal pancreatic endocrine tumors. There is sufficient evidence that octreotide is effective against the following tumors: carcinoid tumors with carcinoid syndrome; VIP tumors, etc., octreotide is about 50% effective against the following tumors.
(1) Gastrinoma/Zollinger-Ellison Syndrome (usually in combination with a selective H2 receptor antagonist, and an antacid may be added as appropriate).
(2) Islet tumors (for the prevention of hypoglycemia before the operation of islet tumors, maintaining normal blood sugar).
(3) Growth hormone releasing factor tumor. Treatment with octreotide acetate only reduces symptoms and signs, but does not cure.
Octreotide acetate microspheres for injection: This product is used forAcromegalyFor the treatment of the following acromegaly patients: after subcutaneous injection of standard dose of Shan Ning, the condition is fully controlled; patients who are not suitable for surgery, radiotherapy or treatment, or in the potential reaction stage before radiotherapy is fully effective Patient. Patients with gastrointestinal pancreatic endocrine tumors associated with functional gastrointestinal pancreatic endocrine tumor-related symptoms have been adequately controlled by subcutaneous injection of Shan Ning. Carcinoid with the characteristics of carcinoid syndrome. Vasoactive intestinal peptide tumor. Glucagonoma. Gastrinoma / Zhuo-Ai syndrome. Insulinoma (for prevention and maintenance of preoperative hypoglycemia). Growth hormone releasing factor adenoma.
Octreotide acetate for injection:
1. Emergency treatment of esophageal-gastric varices bleeding caused by cirrhosis, combined with special treatment (such as endoscopic sclerotherapy).
2. Prevention of postoperative complications of the pancreas.
3. Alleviate the symptoms and signs associated with gastrointestinal endocrine tumors. There is evidence that this product is effective against the following tumors: carcinoid tumors with carcinoid syndrome; VIP tumors; glucagonoma. This product has an effective rate of about 50% for the following tumors (there are limited cases of treatment with this product to date): gastrinoma/Zollinger-Ellison syndrome. Islet tumor. Growth hormone releasing factor tumor.
4. Patients with acromegaly who have failed surgery or radiation therapy or dopamine agonist therapy can control symptoms and reduce the concentration of growth hormone (GH) and auxin medium C.
Octreotide acetate injection:
1. Emergency treatment of esophageal-gastric varices bleeding caused by cirrhosis, combined with special treatment (such as endoscopic sclerotherapy).
2. Alleviate the symptoms and signs associated with gastrointestinal pancreatic endocrine tumors. There is sufficient evidence that octreotide is effective against the following tumors: carcinoid tumors with carcinoid syndrome; VIP tumors, etc., octreotide is about 50% effective against the following tumors.
(1) Gastrinoma/Zollinger-Ellison Syndrome (usually in combination with a selective H2 receptor antagonist, and an antacid may be added as appropriate).
(2) Islet tumors (for the prevention of hypoglycemia before the operation of islet tumors, maintaining normal blood sugar).
(3) Growth hormone releasing factor tumor. Treatment with octreotide acetate only reduces symptoms and signs, but does not cure.

【Dosage】
Octreotide acetate:
1, esophageal - gastric varices bleeding continuous intravenous infusion of 0.025 mg / hour. It can be treated for up to 5 days and can be diluted with physiological saline or diluted with glucose solution.
2, prevention of complications after pancreatic surgery 0.1 mg subcutaneous injection, 3 times a day, continuous treatment for 7 days, the first injection should be performed at least 1 hour before surgery.
3, the initial dose of gastrointestinal pancreatic endocrine tumor is 0.05 mg subcutaneous injection, one to two times a day, and then gradually increase the dose to 0.2 mg according to tolerance and efficacy, three times a day.
4. The initial dose of acromegaly is 0.05-0.1 mg subcutaneously, once every 8 hours, and then adjusted according to monthly assessment of circulating GH concentration, clinical response and tolerability.
Octreotide Acetate Microspheres for Injection: This product can only be administered by deep injection into the buttocks muscle, but never by intravenous injection. If you penetrate the blood vessel, you need to change the injection site. Repeated injections should take turns to select different hip muscle injections on the left or right side. Acromegaly is recommended for patients who have complete control of the standard dose of subcutaneous injection of Shan Ning. The recommended initial dose of this product is 20 mg, administered once every 4 weeks for a total of 3 months. Treatment can begin 1 day after the last subcutaneous injection of Shan Ning. Thereafter the dose should be based on the concentration of serum GH and growth factor C (IGF-1) as well as clinical signs and symptoms. If clinical signs and symptoms and biochemical parameters (GH and IGF-1) are not fully controlled (GH > 2.5 ug/L) after 3 months, the dose should be increased to 30 mg once every 4 weeks.
Octreotide acetate for injection:
1. Esophagus - bleeding of gastric varices. Continuous intravenous infusion of 0.025 mg / hour. It can be treated for up to 5 days and can be diluted with physiological saline or diluted with glucose solution.
2. Prevention of complications after pancreatic surgery. 0.1 mg subcutaneously, 3 times a day for 7 days, the first injection should be performed at least 1 hour before surgery.
3. gastrointestinal pancreatic endocrine tumors. The initial dose is 0.05 mg subcutaneously, one to two times a day, and then gradually increased to 0.2 mg three times a day according to tolerance and efficacy.
4. Acromegaly. The initial dose is 0.05-0.1 mg subcutaneously, once every 8 hours, and then adjusted according to monthly assessment of circulating GH concentration. Clinical response and tolerability.
Octreotide acetate injection:
1. Esophagus-gastric varices bleeding first 0.1mg intravenous bolus (5 minutes), then 0.6mg dissolved in 5% glucose 500ml, continuous intravenous infusion through the infusion pump at 50μg / hour, 12 hours once . Treat for up to 5 days.
2. The initial amount of gastrointestinal pancreatic endocrine tumor is 0.05 mg subcutaneous injection, one to two times a day. The dose can be gradually increased to 0.2 mg three times a day based on tolerance and efficacy (clinical response, hormone concentration secreted by the tumor). In some cases, larger doses may be used. The maintenance amount should be based on individual differences. After the clinical symptoms and laboratory tests showed no improvement, the medication should not exceed one week.

[Storage]
Octreotide acetate: shading, sealed, stored in a cold place (2-10 ° C).
Octreotide acetate microspheres for injection: sealed and stored in a cool place.
Octreotide acetate for injection: sealed.
Octreotide acetate injection: shading, sealed, stored in a cold place (2-10 ° C).

[Tips] Some of the information on this site comes from the Internet and is only used internally by pharmacists or medical staff. It is not a substitute for doctors to diagnose face to face. Please consult a professional pharmacist for specific medications. Please refer to the actual product manual or the actual product for the product content.

name

Attention: The internal data of table “525” is corrupted!

product

Attention: The internal data of table “526” is corrupted!

product manual

Click to view octreotide Chinese product description

Product information